

## LIST OF SCHEMES AND FIGURES

<b>Figure No.</b>	<b>Title</b>	<b>Page</b>
Scheme 2.1:	Short-course Chemotherapy Treatment for New Tuberculosis Cases, Adults >50 kg	37
Scheme 4.1:	TFH and REV process stages in the preparation of INH liposomes	108
Scheme 4.2:	TFH and REV process stages in the preparation of RFP liposomes	112
Figure 2.1:	Mechanisms of particle deposition in the airways	23
Figure 2.2:	The structure of multilamellar vesicles showing the organization of phospholipid bilayers and the encapsulation of lipophilic and hydrophilic compounds	41
Figure 4.1:	DSC thermograph a) INH; b) EDTA; c) INH: EDTA complex arrow showing the absence of EDTA peak	126
Figure 4.2:	IR spectrum a) INH; b) EDTA; c) INH: EDTA complex	127
Figure 4.3:	NMR spectrum a) INH; b) EDTA; c) INH: EDTA complex	128
Figure 4.4:	Photomicrographs showing liposomal vesicles under normal light for INH17	133
Figure 4.5:	Photomicrographs showing liposomal vesicles under dark background and polarized lens for RFP17	133
Figure 5.1:	Effect of cryoprotectant type/concentration on mean particle size of rehydrated INH LDP	161
Figure 5.2:	Effect of cryoprotectant type/concentration on mean particle size of rehydrated RFP LDP	161
Figure 5.3:	Photomicrograph of liposomal dry powder formulation under polarized light	163
Figure 5.4:	Photomicrograph of liposomal vesicles after hydration of liposomal dry powder formulation under polarized light	163
Figure 5.5:	SEM photomicrographs of INH70	164
Figure 5.6:	SEM photomicrographs of RFP70	164
Figure 5.7:	In vitro deposition of INH and RFP LDPI formulations in NGI	166

Figure 5.8.	INH liposomal dry powder moisture sorption	168
Figure 5.9:	RFP liposomal dry powder moisture sorption	168
Figure 6.1:	DSC thermograph of RFP LDPI formulation	183
Figure 6.2:	Stability profiles - INH70 A) PDR, B) Mean size and C) FPF vs. time in months	185
Figure 6.3:	Stability profiles - INH71 A) PDR, B) Mean size and C) FPF vs. time in months	186
Figure 6.4:	Stability profiles – RFP70 A) PDR, B) Mean size and C) FPF vs. time in months	187
Figure 6.5:	Stability profiles – RFP71 A) PDR, B) Mean size and C) FPF vs. time in months	188
Figure 7.1:	In vitro diffusion profile of INH plain drug and LDPI formulations	199
Figure 7.2:	In vitro diffusion profile of RFP plain drug and LDPI formulations	199
Figure 7.3:	Photomicrograph of alveolar macrophage (A) before and (B) after liposomal uptake	200
Figure 8.1.	Drug level in biological samples following instillation of INH plain drug and liposomal	209
Figure 8.2:	Drug level in biological samples following instillation of RFP plain drug and liposomal DPI	211